Abstract Library

#4124 Evaluating a possible association between promoter methylation level of genes encoding catecholamine metabolizing enzymes and metanephrine secretion in pheochromocytoma and paraganglioma

Introduction: Paragangliomas (PPGLs) are rare neuroendocrine tumors that may secrete catecholamines and their metabolites (metanephrines [MN], normetanephrine [NMN]). Secretion patterns differ by adrenal/extra-adrenal origin and genetic alteration. Catecholamines synthesis is carried by phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), aromaticL-aminoacid decarboxylase (AADC), dopamine β-hydroxylase (DBH) and phenylethanolamine N-methyltransferase (PNMT). However, their regulation in PPGL is not entirely understood.

Conference:

Presenting Author: Tirosh A

Authors: Kaplinsky A, Halperin R, Shlomai G, Tirosh A,

Keywords: ppgl, methylation, catecholamine, pseudohypokia, metanephrine, kinase signaling, pheochromocytoma, paraganglioima,

#3505 DRD2 agonist cabergoline abolished the escape mechanism induced by mTOR inhibitor everolimus in pituitary neuroendocrine tumoral cells

Introduction: The mTOR inhibitor everolimus displays antimitotic effects on diverse neoplasms, including pituitary neuroendocrine ones (PitNETs); however, its effect is reduced by an escape mechanism that increases AKT phosphorylation (p-AKT) leading to survival pathway activation. Dopamine receptor type 2 (DRD2) reduces p-AKT in some non-functioning PitNETs (NF-PitNETs) and in lactotrophs MMQ cells, through a β-arrestin2-dependent mechanism.

Conference:

Presenting Author:

Authors: Mangili F, Esposito E, Treppiedi D, Catalano R, Marra G,

Keywords: pituitary neuroendocrine tumor, everolimus, mTOR/AKT pathway, β-arrestin 2, dopamine receptor type 2, cabergoline,

#3319 The rotenone-induced rat model of Parkinson's disease: Morphological and electrophysiological findings

Introduction: Rotenone is a pesticide, which causes behavioral, biochemical and morphological changes in rats and reproduces features of Parkinson's disease, including selective nigrostriatal dopaminergic degeneration.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hambrdzumyan L

Authors: Hambardzumyan L, Darbinyan L, Manukyan L,

Keywords: Rotenon, Parkinson's disease,

#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture

Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martínez A

Authors: Herrera-Martínez A, Van Dungen R, Van Koetsveld P, Dogan-Oruc F, Culler M,

Keywords: NETs, somatostatin receptors, dopamine receptors, multi-receptor targeting drugs, hormone secretion,

#2155 Menstrual Dysfunction in Women with Prolactinomas

Introduction: Hyperprolactinemia syndrome (HPS) is a set of symptoms with typical increase in serum prolactin accompanied by galactorrhea, hypogonadism and potential infertility

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Safarova M, Khalimova Z, Axmedova S, Issaeva S, Gumarova A,

Keywords: prolactinoma, hyperprolactinemia, dopamine agonists,